Evidence map›Paper›PMID 41660277›Full record

ReviewFrontiers in cell and developmental biology2026

Ferroptosis and Alzheimer's disease: unraveling the molecular mechanisms and therapeutic opportunities.

Yuan Fang, Zhongyu Han, Siming Yang, Juncheng Chen, Ruobing Li, Zhexu Zhang, Junhui Song, Danyan Wang, Yunqing Ban

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuan Fang *The Fifth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Zhongyu Han *Institute of Nephrology, Zhongda Hospital, Southeast University, Nanjing, China.
Siming Yang *Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Juncheng ChenThe Fifth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Ruobing LiThe Fifth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Zhexu ZhangThe Fifth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Junhui SongThe Fifth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Danyan WangThe Affiliated Hospital of Qingdao Binhai University, Qingdao, China.
Yunqing BanThe Fifth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a novel form of regulated cell death. Compared with other types of cell death, it shows great differences in structure and biochemistry. This type of cell death is receiving increasing attention. For example, studies have found that it plays a key role in the development of neurodegenerative diseases underlying brain atrophy, such as Alzheimer's disease (AD). AD is a chronic and worsening neurodegenerative disease. It poses a serious threat to the health and quality of life of the elderly. The pathology of AD is mainly the presence of extracellular beta-amyloid (Aβ) plaques and intracellular tau-based nerve fiber entanglement (NFTs). Although there are a large number of studies and interventions for AD, so far, no clinical drugs have been found that can stop the pathological progression of AD or cure it. Currently, treatment strategies for this disease only focus on alleviating clinical symptoms and do not achieve slowing disease progression or curing it. Ferroptosis is gradually considered to play a key role in the occurrence and development of AD. Research based on the AD model confirms that neuronal ferroptosis can be inhibited through pharmacology to reverse cognitive disorders. In this review, we first describe the key molecular mechanisms of ferroptosis, and then discuss how these mechanisms operate and develop in AD. Then, we give a detailed introduction to the latest treatments for AD, including iron chelators, antioxidants, and specific ferroptosis inhibitors. What is noteworthy is that this article emphasizes the analysis of the mechanisms of iron metabolism disorders, as well as the introduction of new drugs for the prevention, rather than the alleviation of AD.

Indexed as

Alzheimer’s diseaseferroptosisinhibitoriron metabolismmitochondrial

Identifiers

PMID41660277
PMCPMC12876189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.